Weekly Digest - September 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - September 2024
10 Sep 2024: AstraZeneca, Daiichi Sankyo’s Dato-DXd fails to significantly improve overall survival in phase III NSCLC
- The Phase III TROPION-Lung01 study showed datopotamab deruxtecan failed to significantly improve overall survival compared to docetaxel in non-small cell lung cancer patients
- Patients on datopotamab deruxtecan had a mean overall survival of 12.9 months, compared to 11.8 months with docetaxel, with a 6% reduction in the risk of death that lacked statistical significance
- In the non-squamous NSCLC subset, the overall survival benefit of datopotamab deruxtecan showed a nominal 16% improvement but also missed statistical significance
- AstraZeneca and Daiichi Sankyo reported disappointing results in May 2024 but remain confident in datopotamab deruxtecan’s potential; the FDA’s target action date for approval is 20 December 2024
